Case Report: Short-term disease control with subsequent icotinib therapy in EGFR L858R/C797S, T790M-negative lung adenocarcinoma after osimertinib resistance.

Authors

Shihang Song, Di Yao, Jinlong Liu, Wenjing Nie, Mengjia He, Jianqiao Zhang, Jing Zhao

Published in

Frontiers in oncology. Volume 16. Pages 1911991. Epub Jul 20, 2026.

Abstract

Osimertinib resistance, particularly EGFR C797S without T790M, lacks established treatment strategies. We report a 71-year-old woman with stage IVB lung adenocarcinoma harboring EGFR L858R (T790M-negative) who received first-line osimertinib for 29 months until progression. Post-progression ctDNA revealed L858R/C797S (T790M-negative) who received first-line osimertinib for 29 months until progression. Post-progression ctDNA revealed L858R/C797S (T790M-negative). She was subsequently treated with icotinib 125 mg tid, achieving stable disease for 6 months. This case suggests that first-generation EGFR-TKI subsequent therapy may provide short-term disease control in this rare molecular context.

PMID:
42548887
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.